RedHill Biopharma Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDHL research report →
Companywww.redhillbio.com
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
- CEO
- Dror Ben-Asher
- IPO
- 2013
- Employees
- 35
- HQ
- Tel Aviv, IL
Price Chart
Valuation
- Market Cap
- $2.89M
- P/E
- -0.25
- P/S
- 0.42
- P/B
- 0.39
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 63.30%
- Op Margin
- -109.48%
- Net Margin
- -98.66%
- ROE
- 291.07%
- ROIC
- -118.53%
Growth & Income
- Revenue
- $286.00K · -96.44%
- Net Income
- $-429,000 · 94.81%
- EPS
- $0.00 · 100.00%
- Op Income
- $-7,909,000
- FCF YoY
- -2.96%
Performance & Tape
- 52W High
- $3.31
- 52W Low
- $0.71
- 50D MA
- $0.90
- 200D MA
- $1.21
- Beta
- 5.04
- Avg Volume
- 59.30K
Get TickerSpark's AI analysis on RDHL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 6, 26 | Raday Gilead | sell | 15,740,000 |
| Apr 6, 26 | Raday Gilead | other | 30,780,000 |
| Mar 18, 26 | Tsimchi Ofer | other | 0 |
| Mar 18, 26 | Tsimchi Ofer | other | 36,440,000 |
| Mar 18, 26 | Tsimchi Ofer | other | 180,000 |
| Mar 18, 26 | Scruggs Rick D | other | 0 |
| Mar 18, 26 | Scruggs Rick D | other | 73,640,000 |
| Mar 18, 26 | Scruggs Rick D | other | 840,000 |
| Mar 18, 26 | Reed Kenneth | other | 0 |
| Mar 18, 26 | Reed Kenneth | other | 25,830,000 |
Our RDHL Coverage
We haven't published any research on RDHL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RDHL Report →